1-5 of 5
Eric Rubin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years

Pedro Barata, Brian Hobbs, Brian Rini, Channing Paller, Dan Normolle, Elizabeth Garrett-Mayer, Eric Rubin, Gary Rosner, Greg Pond, Jane Perlmutter, Lesley Seymour, Lillian Siu, Nolan Wages, Percy Ivy, Tatiana Prowell, Timothy Yap, David Hong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A100.
https://doi.org/10.1158/1535-7163.TARG-17-A100
Published: 01 January 2018
View article titled, Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years
Journal Articles

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

Yan Cheng, Yi Zhang, Li Zhang, Xingcong Ren, Kathryn J. Huber-Keener, Xiaoyuan Liu, Lei Zhou, Jason Liao, Heike Keihack, Li Yan, Eric Rubin, Jin-Ming Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 154–164.
https://doi.org/10.1158/1535-7163.MCT-11-0606
Published: 09 January 2012
View article titled, MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Open the PDF for MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis in another window
Includes: Supplementary data
Journal Articles

Phase I study of Ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies

Antoinette Tan, Tarek Mekhail, Martin Edelman, Eric Rubin, Lisa Iacono, Greg Linowski, Ovid Trifan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C158.
Published: 01 November 2007
View article titled, Phase I study of Ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies
Journal Articles

A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors

Jordi Rodon, Amita Patnaik, Mark Stein, Anthony Tolcher, Chee Ng, Cinara Dias, Gerard Greig, Stanley Frankel, Razelle Kurzrock, Eric Rubin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A77.
Published: 01 November 2007
View article titled, A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors
Journal Articles

Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors

Mace Rothenberg, Elizabeth Poplin, Alan Sandler, Eric Rubin, F Fox, J Schwartz, Wendy Vermeulen, Hagop Youssoufian
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C84.
Published: 01 November 2007
View article titled, Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG<sub>1</sub> monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors